The initial success of Sildenafil undeniably transformed the pharmaceutical landscape, but betting in companies primarily reliant on off-patent versions presents a uncertain picture. Although early earnings were significant, the cessation of patents and the rise of cheaper alternatives have diminished market share. Consequently, a thorough analysis